- Haematology Testing Kits
- Urinalysis Testing Kits
- Others
Infectious Disease Point Of Care Diagnostics Market size was valued at USD 2,547.8 million in 2022 and is poised to grow at a significant CAGR of 7.2% from 2023-2029 Moreover, the technological advancements in point-of-care diagnostic devices and introduction of home-based point-of-care devices are also anticipated to boost the infectious disease point of care diagnostics market. However, reluctance among patients to change existing diagnostic practices, stringent regulatory policies, and reimbursement issues might restrain the growth of the global infectious disease point-of-care diagnostics market over the forecast timeframe. Point of care diagnostics refers to the tests carried out at the site of the patient care to provide immediate results. These diagnostics improve disease management and detection. Infectious diseases are caused by various microorganisms such as viruses, bacteria, fungi, and parasites. Infectious disease point-of-care diagnostics reduces the time between disease testing and diagnosis of an infection.
Nowadays most infectious diseases such as HIV, tuberculosis, influenza, tropical diseases, and sexually transmitted infections are diagnosed by point-of-care testing. The major advantages with the point of point-of-care testing are reduced diagnosis time, postoperative care time, improvement in disease outcomes, accuracy in results, and simple methods for diagnosis of infectious diseases. The global infectious disease point-of-care diagnostics market is in the flourishing stage as several local and international players are actively involved in the development of infectious disease point-of-care diagnostic devices. An increase in the prevalence of the deadly infectious disease will drive the growth of the global infectious disease point-of-care diagnostics market. For instance, according to World Health Organisation, global health observatory (GHO) data, in 2013, approximately 34-38 million people suffered from HIV infection worldwide. Launching of new products, approvals from various regulatory bodies, acquisitions and mergers, partnerships, collaborations, and joint ventures are expected to fuel the growth of the global infectious disease point-of-care diagnostics market over the forecast period. For instance,
Infectious Disease Point Of Care Diagnostics Market Key Developments:
Study Period
Base Year
CAGR
Largest Market
Fastest Growing Market
Increase in the incidence and prevalence of infectious diseases such as malaria, dengue, HIV, rise in healthcare expenditure, growing investments from public and private sectors for the development of new products, rising government support towards the adoption of point of care devices are expected to drive global infectious disease point of care diagnostics market over the forecast period.
The infectious disease point of care diagnostics market size was valued at USD x million in 2022
The infectious disease point of care diagnostics market key players are: Cepheid Inc. (Danaher Corporation) (U.S.) Abbott Laboratories, Inc. (U.S.) F. Hoffmann La Roche Limited (Switzerland) Beckman Coulter, Inc. (U.S.) Siemens Healthcare GmbH (Germany) Johnson & Johnson Services, Inc. (U.S.) Instrumentation Laboratory (U.S.) Becton, Dickinson and Company (U.S.) Alere Inc. (U.S.) Nova Biomedical (U.S.) Thermo Fisher Scientific (U.S.) Quidel Corporation (U.S.)
The infectious disease point of care diagnostics market has been classified into North America, Asia Pacific, Europe, Latin America, Middle East and Africa, and the rest of MEA.